Press Room
  Date Title View
Jul 17, 2000
San Mateo, CA, July 17, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN), a global specialty biopharmaceutical company targeting cancer, infectious diseases and cystic fibrosis, today announced record results for the second quarter ended June 30, 2000.Revenues for the second quarter of 2000 from sales of ZADAXIN®...
PDF
Jun 6, 2000
San Mateo, CA, June 6, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for use of the Company's lead drug, ZADAXINÃ’, for the treatment of hepatitis B. ZADAXIN is the safe, synthetic preparation of thymosin alpha 1...
PDF
May 23, 2000
San Mateo, CA, May 23, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced at the UBS Warburg Global Specialty Pharmaceuticals Conference that ZADAXIN, the Company's lead immunotherapy, is now commercially available in Italy. This represents the first commercial launch of ZADAXIN in a Europe...
PDF
May 22, 2000
San Mateo, CA, May 22, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced that in a study presented today in a poster session at the Annual Meeting of the American Society of Clinical Oncology (ASCO), independent investigators concluded that ZADAXIN, SciClone's lead immunotherapy, can significant...
PDF
May 17, 2000
San Mateo, CA, May 17,2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced at the H.C. Wainwright & Co., Inc. Emerging Growth Stock Conference that the U.S. Patent & Trademark Office has granted the Company an important patent concerning the use of DAX (3-diallyl-8-cyclohexylxanthine) as a tr...
PDF
Apr 27, 2000
San Mateo, CA, April 27, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that first quarter 2000 sales of ZADAXIN, the Company's lead immunotherapy, were $3,499,000, an increase of 122% over first quarter 1999 ZADAXIN sales of $1,577,000. For the first quarter of 2000, the net loss of $875,000 decreased 67% when compare...
PDF
Apr 13, 2000
San Mateo, CA, April 13, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced the approval of ZADAXIN, its lead immunotherapy, in South Korea, one of the world's largest pharmaceutical markets. The South Korean approval is for use of ZADAXIN as an influenza vaccine adjuvant by individuals wit...
PDF
Apr 6, 2000
San Mateo, CA, April 6, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced today that a study published in the peer-reviewed journal Melanoma Research (Volume 10, Issue 2, April 2000) suggests that ZADAXINÃ’, SciClone's lead immunotherapy, increases the effectiveness of chemotherapy for metastatic...
PDF
Mar 22, 2000
San Mateo, CA, March 22, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status to ZADAXIN®, SciClone's lead immunotherapy, for the treatment of hepatocellular carcinoma,...
PDF
Mar 17, 2000
San Mateo, CA, March 17, 2000 - SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that ZADAXIN, the Company's lead immunotherapy, has been approved for marketing in Thailand, Laos and Malta. ZADAXIN now is approved for marketing in 19 countries, principally for treatment of hepatitis B and hepatit...
PDF
FirstPrevious
...
40
NextLast